Aptose Biosciences Inc. (APTO) 6.37 $APTO
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), CLDN: 13.68 (-0.26), APS.TO: 7.70 (-0.09), PFBX: 9.33 (+0.12), VLTC: 11.54 (+0.50), APTO: 6.37 (-0.01), ALDX: 9.56 (-0.18), SNAK: 8.71 (-0.69), CLFD: 14.25 (+0.04), ASMB: 15.45 (-1.54), SGC: 19.02 (-0.08), ADTN: 15.98 (-0.03), CREE: 31.87 (-0.36)
Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board
PR Newswire - Mon Mar 23, 7:30AM CDT
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced the appointment of Michael Andreeff, M.D., Ph.D., Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (MDACC), to its Scientific Advisory Board.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference
CNW Group - Mon Mar 23, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 12(th) Annual BIO Asia International Conference on Tuesday, March 24(th) at 1:15 p.m. JST at the Grand Hyatt, Tokyo, Japan. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences reports 4Q loss
Automated Insights - Tue Mar 03, 3:45PM CST
TORONTO (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $3.6 million in its fourth quarter.
APTO: 6.37 (-0.01)
Aptose Biosciences reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:41PM CST
APTO: 6.37 (-0.01)
Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference
CNW Group - Thu Feb 19, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming RBC Capital Markets 2015 Global Healthcare Conference on Tuesday, February 24th at 1:35 p.m. ET at the Kennedy 1 Room at the New York Palace Hotel in New York City. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
What's New in the Pharma Sector: New Research on Amgen, Applied Genetic Technologies, Aptose, ARIAD, and Atara Biotherapeutics
PR Newswire - Fri Feb 13, 6:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AGTC: 21.74 (+0.52), APTO: 6.37 (-0.01), AMGN: 167.91 (-1.26), ATRA: 59.89 (-4.13), ARIA: 9.71 (+0.10)
Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee
CNW Group - Tue Jan 20, 4:02PM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that Dr. Bradley Thompson has been appointed to the Audit Committee, and that the NASDAQ Stock Market ("NASDAQ"
has notified the Company it has regained compliance with Listing Rule 5605 to maintain three independent members on the Audit Committee.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
PR Newswire - Tue Jan 13, 5:45PM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. APTO-253 is a first-in-class inducer of the Krüppel-like factor 4 (KLF4) tumor suppressor gene, and the only clinical-stage compound targeted for patients with suppressed KLF4 levels.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at Biotech Showcase(TM) 2015
CNW Group - Mon Jan 12, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 7(th) Annual Biotech Showcase Conference on January 13(th) at 4:00 p.m. PST at the Powell Room at the Parc 55 Wyndham Hotel in San Francisco, CA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at Biotech Showcase™ 2015
PR Newswire - Mon Jan 12, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 7th Annual Biotech Showcase Conference on January 13th at 4:00 p.m. PST at the Powell Room at the Parc 55 Wyndham Hotel in San Francisco, CA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Tiny Aptose Biosciences Looks Worth A Closer Look
Stephen Simpson, CFA - at Seeking Alpha - Tue Dec 30, 2:49PM CST
APTO: 6.37 (-0.01)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), CLDN: 13.68 (-0.26), APS.TO: 7.70 (-0.09), PFBX: 9.33 (+0.12), VLTC: 11.54 (+0.50), APTO: 6.37 (-0.01), ALDX: 9.56 (-0.18), SNAK: 8.71 (-0.69), CLFD: 14.25 (+0.04), ASMB: 15.45 (-1.54), SGC: 19.02 (-0.08), ADTN: 15.98 (-0.03), CREE: 31.87 (-0.36)
Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board
PR Newswire - Mon Mar 23, 7:30AM CDT
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced the appointment of Michael Andreeff, M.D., Ph.D., Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (MDACC), to its Scientific Advisory Board.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference
CNW Group - Mon Mar 23, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 12(th) Annual BIO Asia International Conference on Tuesday, March 24(th) at 1:15 p.m. JST at the Grand Hyatt, Tokyo, Japan. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences reports 4Q loss
Automated Insights - Tue Mar 03, 3:45PM CST
TORONTO (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $3.6 million in its fourth quarter.
APTO: 6.37 (-0.01)
Aptose Biosciences reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:41PM CST
APTO: 6.37 (-0.01)
Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference
CNW Group - Thu Feb 19, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming RBC Capital Markets 2015 Global Healthcare Conference on Tuesday, February 24th at 1:35 p.m. ET at the Kennedy 1 Room at the New York Palace Hotel in New York City. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
What's New in the Pharma Sector: New Research on Amgen, Applied Genetic Technologies, Aptose, ARIAD, and Atara Biotherapeutics
PR Newswire - Fri Feb 13, 6:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AGTC: 21.74 (+0.52), APTO: 6.37 (-0.01), AMGN: 167.91 (-1.26), ATRA: 59.89 (-4.13), ARIA: 9.71 (+0.10)
Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee
CNW Group - Tue Jan 20, 4:02PM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that Dr. Bradley Thompson has been appointed to the Audit Committee, and that the NASDAQ Stock Market ("NASDAQ"
has notified the Company it has regained compliance with Listing Rule 5605 to maintain three independent members on the Audit Committee. APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
PR Newswire - Tue Jan 13, 5:45PM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. APTO-253 is a first-in-class inducer of the Krüppel-like factor 4 (KLF4) tumor suppressor gene, and the only clinical-stage compound targeted for patients with suppressed KLF4 levels.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at Biotech Showcase(TM) 2015
CNW Group - Mon Jan 12, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 7(th) Annual Biotech Showcase Conference on January 13(th) at 4:00 p.m. PST at the Powell Room at the Parc 55 Wyndham Hotel in San Francisco, CA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Aptose Biosciences to Present at Biotech Showcase™ 2015
PR Newswire - Mon Jan 12, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 7th Annual Biotech Showcase Conference on January 13th at 4:00 p.m. PST at the Powell Room at the Parc 55 Wyndham Hotel in San Francisco, CA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction including plans to develop Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
APTO: 6.37 (-0.01), APS.TO: 7.70 (-0.09)
Tiny Aptose Biosciences Looks Worth A Closer Look
Stephen Simpson, CFA - at Seeking Alpha - Tue Dec 30, 2:49PM CST
APTO: 6.37 (-0.01)
